Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa
International Journal of Molecular Sciences · 24.09.2024 · 25 (19) · 10270
DOI: 10.3390/ijms251910270 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.09.2024. Verfasst von Alla Zorina und 6 weiteren Autor:innen. Beteiligte Einrichtung: Artgen Biotech, Moscow 119333, Russia. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Dystrophica, Genetic Therapy, Cell- and Tissue-Based Therapy, Collagen Type VII. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
This detailed review describes innovative strategies and current products for gene and cell therapy at different stages of research and development to treat recessive dystrophic epidermolysis bullosa (RDEB) which is associated with the functional deficiency of collagen type VII alpha 1 (C7) caused by defects in the COL7A1 gene. The use of allogenic mesenchymal stem/stromal cells, which can be injected intradermally and intravenously, appears to be the most promising approach in the field of RDEB cell therapy. Injections of genetically modified autologous dermal fibroblasts are also worth mentioning under this framework. The most common methods of RDEB gene therapy are gene replacement using viral vectors and gene editing using programmable nucleases. Ex vivo epidermal transplants (ETs) based on autologous keratinocytes (Ks) have been developed using gene therapy methods; one such ET successively passed phase III clinical trials. Products based on the use of two-layer transplants have also been developed with both types of skin cells producing C7. Gene products have also been developed for local use. To date, significant progress has been achieved in the development of efficient biomedical products to treat RDEB, one of the most severe hereditary diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Artgen Biotech, Moscow 119333, Russia.
- Skincell LLC, Moscow 119333, Russia.
- Department of Pharmacology, The I. M. Sechenov First Moscow State Medical University (The Sechenov University), Moscow 119991, Russia.
- Department of Pharmacognosy and Industrial Pharmacy, Lomonosov Moscow State University, Moscow 119992, Russia.
- Department of Plastic and Reconstructive surgery, Cosmetology and Cell Technologies, Pirogov Russian National Research Medical University, Moscow 117997, Russia.
- JSC Plastic Surgery and Cosmetology Institute, Moscow 125047, Russia.
ORCID-Profile: Pavel Kopnin
Förderung
- Russian Science Foundation
Zitieren
APA
Zorina, A., Zorin, V., Isaev, A., Kudlay, D., Manturova, N., Ustugov, A., & Kopnin, P. (2024). Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa. International Journal of Molecular Sciences, 25(19), 10270. https://doi.org/10.3390/ijms251910270
Vancouver
Zorina A, Zorin V, Isaev A, Kudlay D, Manturova N, Ustugov A, et al. Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa. International Journal of Molecular Sciences. 2024;25(19):10270. doi:10.3390/ijms251910270
BibTeX
@article{Zorina2024,
author = {Zorina, Alla and Zorin, Vadim and Isaev, Artur and Kudlay, Dmitry and Manturova, Natalia and Ustugov, Andrei and Kopnin, Pavel},
title = {Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {19},
pages = {10270},
doi = {10.3390/ijms251910270}
}
EUVIMED